Press releases

Press release
Good market uptake for Simeprevir during the first quarter 2014

Stockholm, Sweden — Medivir AB (OMX: MVIR) announces a good market uptake and strong sales development for simeprevir during the first...

Read more
Press release
Final data from the phase II COSMOS study with Simeprevir in combination with Sofosbuvir presented at EASL

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that positive new simeprevir data were presented at The International Liver Congress™...

Read more
Press release
Annual Report 2013

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that the Annual Report for 2013 now is available at the company’s...

Read more
Press release
Notice of Annual General Meeting of Medivir AB (publ)

The shareholders in Medivir AB are hereby summoned to the annual general meeting on Thursday 8 May 2014 at 2 p.m....

Read more
Press release
Two phase III trials evaluating once-daily Simeprevir and Sofosbuvir in hepatitis C infected patients have been initiated

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that two phase III trials are recruiting patients to examine the efficacy...

Read more
Press release
New Simeprevir data will be presented at The International Liver Congress 2014 of the European Association for the Study of the Liver, (EASL)

Presentations Include late-breaking final results from the phase II COSMOS study Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that...

Read more
Press release
Simeprevir has now been approved in Russia

Stockholm, Sweden — Medivir AB (OMX: MVIR) announced today that that the Russian Ministry of Health has approved Sovriad® (simeprevir) for...

Read more
Press release
Simeprevir receives positive CHMP opinion for the treatment of adults with chronic hepatitis C in the European Union

Positive opinion for the use of simeprevir in combination with other medicinal products for the treatment of chronic hepatitis C (CHC)...

Read more
Press release
New Phase III Data from Once-Daily Simeprevir Presented at the Conference of the Asian Pacific Association for the Study of the Liver (APASL)

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announced that new phase III data for the once-daily protease inhibitor simeprevir have...

Read more
Press release
The Nomination Committee’s proposal, with reference to the upcoming 2014 Annual General Meeting, for a new Board of Directors

Stockholm, Sweden — Medivir AB (OMX: MVIR) announced today the Nomination Committee’s proposal, with reference to the upcoming 2014 Annual General...

Read more
Press release
SVR12 results from a phase IIa study evaluating Simeprevir and Daclatasvir in Hepatitis C patients of genotype 1 have been presented

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announced that study results from a phase IIa trial evaluating simeprevir, a once-daily...

Read more
Press release
Financial Statement, 1 January – 31 December 2013*

Financial summary for the year as a whole. Continuing Group operations, excluding Cross Pharma. Net turnover totalled SEK 446.1 million (SEK...

Read more